Search Results for: mesenchymal

Mesenchymal cells or MSCs: definition, clinical potential, challenges

mesenchymal cells, MSCs, mesenchymal stem cells, multipotent stem cells

I confess that I’m old enough to remember when the acronym MSC stood unambiguously for “mesenchymal stem cells”, but should it refer to a broader term like “mesenchymal cells”? The field has moved in that direction. I think that’s the best way to go too and I’ll explain why. The goal of today’s post is […]

Mesenchymal cells or MSCs: definition, clinical potential, challenges Read More »

Q&A with Kyle Cetrulo of The Perinatal Stem Cell Society on the FDA, state laws, & more

Kyle Cetrulo, Perinatal Stem Cell Society

I was interested to see that an organization called The Perinatal Stem Cell Society seems to have been upbeat about the new Utah stem cell law. That law sets up a likely conflict with the FDA and federal law over stem cells. In a nutshell, Utah now says you can sell non-FDA-approved stem cells in

Q&A with Kyle Cetrulo of The Perinatal Stem Cell Society on the FDA, state laws, & more Read More »

Recent stem cell & regenerative medicine good news

stem cell good news, good news

Looking for some stem cell good news? You’ll like today’s post. One mission of this blog The Niche is to promote rigorous science-based regenerative medicine, which can lead to investigating and writing about not-so-upbeat stuff. Risky clinics. People getting hurt. Patient lawsuits. Serious FDA, FTC, or state AG regulatory developments. Such actions can be good

Recent stem cell & regenerative medicine good news Read More »

Perspectives on new stem cells for paralysis paper & media coverage

stem cells for paralysis

A new paper on stem cells for paralysis from a Mayo Clinic team has sparked a bit of legitimate hope but also some hype in the media. The publication was in Nature Communications. It is entitled “Intrathecal delivery of adipose-derived mesenchymal stem cells in traumatic spinal cord injury: Phase I trial.” The approach was direct injection

Perspectives on new stem cells for paralysis paper & media coverage Read More »

Weekly reads: Vertex & CRISPR Therapeutics, Arnold Caplan death, MS genetics

CRISPR Therapeutics

The biotechs Vertex and CRISPR Therapeutics have an interesting relationship as biotechs. They are partners are multiple levels but also are very different as companies including in size. There’s been a key development in one of their partnerships. Before we jump into that, please check out the video version of my 20 stem cell and

Weekly reads: Vertex & CRISPR Therapeutics, Arnold Caplan death, MS genetics Read More »

Put on a happy face? Perspectives on Mayo Clinic stem cells for heart disease Ph3 pub

stem cells for heart disease

One of the first regenerative medicine talks I ever saw was on stem cells for heart disease. I was still a trainee at the time. The professor, whom I won’t name, presented data from an early phase trial reporting that direct injections of some kind of cells right into the heart improved outcomes. Stem cells

Put on a happy face? Perspectives on Mayo Clinic stem cells for heart disease Ph3 pub Read More »

Surprising new FDA remarks to AABB on cord biologics misuse & stem cell clinics

AABB, FDA

The Association for the Advancement of Blood & Biotherapies or AABB recently had a very useful Q&A with the FDA on cord blood use. There are some important new things from the FDA on the marketing and use of cord blood in there. The agency was also quite blunt in some ways about the challenges,

Surprising new FDA remarks to AABB on cord biologics misuse & stem cell clinics Read More »

Weekly reads: stem cell therapy for eyes research, DMD, cheating death, cancer sensors

stem cell therapy

Many avenues are being pursued to get stem cell therapy to the clinic for eye conditions. These different approaches employ a variety of stem cell types. In some cases, such as with iPS cells, the stem cells themselves are not transplanted. Instead, the iPS cells are used to make differentiated eye cells, such as RPE

Weekly reads: stem cell therapy for eyes research, DMD, cheating death, cancer sensors Read More »

Weekly reads: BioCardia, HeLa suit, illegal bio lab in CA

mesenchymal cells

A days ago the news came about Mesoblast not getting FDA approval for its MSC product for GvHD. The MSC area has had a rough few years with various clinical trials including for COVID. The “stem cells for heart disease” arena has also had a tough time. Here’s more news along these lines: BioCardia pauses enrollment in PhIII trial

Weekly reads: BioCardia, HeLa suit, illegal bio lab in CA Read More »